Not currently recruiting at University of California Health
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA
- Dates
- study startedcompletion around
- Principal Investigator
- by Saeed Sadeghi (ucla)
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Saeed Sadeghi (ucla)
HS Clinical Professor, Medicine. Authored (or co-authored) 24 research publications
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- TransThera Sciences (Nanjing), Inc.
- ID
- NCT05948475
- Phase
- Phase 3 Cholangiocarcinoma Research Study
- Study Type
- Interventional
- Participants
- Expecting 200 study participants
- Last Updated